PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 235 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... May 7, 2021 An Updated Overview of Estimates for Cancer Incidence and Mortality in... June 23, 2022 EMA Recommends Extension of Indications for Pirtobrutinib April 24, 2025 How MRI add-ons could accelerate the development of new treatments May 9, 2023 Load more HOT NEWS Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC Transforming optimism: finding new ways to treat rare cancers
